AngioDynamics, Inc. ANGO Income Statement

Angiodynamics, inc. (ANGO)

Income statement / Quarterly

Feb'20	Nov'19	Aug'19	May'19	Feb'19	Nov'18	Aug'18	May'18	Feb'18	Nov'17	Aug'17	May'17	Feb'17	Nov'16	Aug'16	May'16	Feb'16	Nov'15	Aug'15	May'15	Feb'15	Nov'14	Aug'14	May'14	Feb'14	Nov'13	Aug'13	May'13	Feb'13	Nov'12	Aug'12	May'12	Feb'12	Nov'11	Aug'11	May'11	Feb'11	Nov'10	Aug'10
Net sales
69,780	70,003	66,042	71,182	65,524	69,985	63,943	5,687	83,851	86,706	85,411	7,059	85,602	89,029	88,098	93,419	87,434	89,284	83,753	90,697	86,597	92,149	87,091	94,060	88,150	88,571	83,644	89,932	81,571	87,007	83,406	57,820	51,567	58,099	54,431	56,223	54,648	53,372	51,507
Cost of sales (exclusive of intangible amortization)
29,481	28,459	27,825	29,850	27,361	29,433	27,990	-8,761	38,403	43,975	44,182	-3,057	41,810	44,019	43,066	51,892	43,900	43,400	40,382	45,366	48,924	45,321	41,127	46,144	43,357	43,686	41,064	46,166	40,370	42,919	43,947	27,302	22,153	24,868	22,285	23,797	22,927	21,836	21,487
Gross profit
40,299	41,544	38,217	41,332	38,163	40,552	35,953	14,448	45,448	42,731	41,229	10,116	43,792	45,010	45,032	41,527	43,534	45,884	43,371	45,331	37,673	46,828	45,964	47,916	44,793	44,885	42,580	43,766	41,201	44,088	39,459	30,518	29,414	33,231	32,146	32,426	31,721	31,536	30,020
Operating expenses:
Research and development
8,395	7,764	6,292	6,893	6,915	7,076	7,374	5,333	6,457	6,107	6,441	5,575	5,951	5,913	6,709	6,937	5,808	6,179	6,129	6,552	6,578	6,276	7,188	7,367	7,045	7,003	6,709	6,438	5,793	7,014	7,074	5,221	4,574	5,125	5,591	5,550	5,322	5,259	5,242
Sales and marketing
20,934	20,113	19,380	20,776	18,385	19,263	18,405	16,731	18,009	18,967	19,402	16,523	19,418	19,469	19,455	20,210	20,955	21,378	21,200	20,281	19,799	21,536	20,735	23,569	20,700	21,073	19,963	20,387	18,520	18,671	18,543	16,548	15,802	15,847	16,308	15,333	14,553	13,793	14,444
General and administrative
10,203	10,994	8,453	8,487	8,718	9,262	8,435	7,672	7,723	7,540	8,056	8,042	7,051	7,839	8,201	7,686	6,901	8,082	7,914	8,317	6,613	7,786	7,315	7,360	6,445	6,411	6,686	6,331	6,046	6,910	6,899	5,662	4,434	4,625	4,312	4,723	4,346	4,173	4,586
Amortization of intangibles
5,000	4,500	3,900	4,500	4,700	4,500	3,400	1,504	4,200	4,100	4,096	1,714	4,360	4,291	4,235	4,608	4,458	4,483	4,415	4,730	5,188	4,011	4,037	3,904	4,248	4,339	4,109	4,459	4,314	4,107	3,737	2,394	2,320	2,300	2,295	2,573	2,252	2,142	2,267
Change in fair value of contingent consideration
419	145	-448	-7,641	609	244	12	32	31	82	105	125	122	-15,951	443	318	-31	306	355	430	-9,794	542	726	573	-4,154	940	733	-	630	197	-	-	0	-	-	-	-	-	-
Acquisition, restructuring and other items, net
1,565	1,421	1,500	5,427	2,550	2,728	4,422	3,500	4,177	4,766	2,989	15,482	1,750	7,861	2,417	3,493	3,042	3,913	2,143	-	18,676	2,062	-	3,176	3,016	2,679	2,002	4,054	5,157	2,067	2,522	8,487	5,041	1,408	923	-	-	772	-
Medical device excise tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	435	978	1,003	-	-	-	-	874	980	999	976	-	683	-	-	-	0	-	-	-	-	-	-
Total operating expenses
46,535	44,967	39,045	38,398	41,837	43,079	42,082	34,741	40,588	41,608	41,089	45,591	38,652	29,422	41,460	43,252	41,568	45,319	43,159	44,202	48,094	43,289	43,660	46,785	38,280	43,444	41,178	43,342	41,143	38,966	38,775	38,312	32,171	29,305	29,429	34,589	26,473	26,139	26,539
Operating loss
-6,236	-3,423	-828	2,934	-3,674	-2,527	-6,129	-20,293	4,860	1,123	140	-35,475	5,140	15,588	3,572	-1,725	1,966	565	212	1,129	-10,421	3,539	2,304	1,131	6,513	1,441	1,402	424	58	5,122	684	-7,794	-2,757	3,926	2,717	-2,163	5,248	5,397	3,481
Other (expenses) income:
Interest expense, net
166	41	465	1,410	1,442	1,330	917	839	740	760	723	683	627	810	719	778	809	998	800	-	-	-	-	534	917	959	1,246	1,285	1,271	1,383	1,332	179	102	111	116	140	119	116	124
Interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	1	1	-	-	-	-	0	0	0	0	0	0	21	82	290	305	260	235	201	208	161	167
Other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	239	-	232	474	374	409	-959	1,053	832	719	883	608	628	588	531	326	506	733	358	267	307	571
Other expense, net
-131	162	-98	-5,234	-266	80	114	-3,331	-49	-280	567	-2,851	44	-363	50	-2,703	-214	-1,236	-118	-977	-1,331	-1,166	-1,208	425	-1,970	-1,791	-1,965	-2,168	-1,879	-1,990	-1,838	-420	-123	-357	-614	-297	-178	-262	-528
Total other expense, net
-297	121	-563	-	-1,708	-1,250	-803	-	-789	-1,040	-156	-	-583	-1,173	-669	-	-1,021	-	-917	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from continuing operations before income tax benefit
-6,533	-3,302	-1,391	1,389	-5,382	-3,777	-6,932	-21,401	4,071	83	-16	-36,170	4,557	14,415	2,903	-2,822	945	-671	-705	152	-11,752	2,373	1,096	1,556	4,543	-350	-563	-1,744	-1,821	3,132	-1,154	-8,214	-2,880	3,569	2,103	-2,460	5,070	5,135	2,953
Income tax benefit
-824	-566	-116	-1,365	-773	-190	-1,228	-941	-9,948	-166	19	-11,197	1,670	681	1,603	40,253	351	-337	70	740	-7,599	1,304	812	3,090	28	-89	-190	-277	-829	1,163	-433	-1,097	-1,112	1,240	730	-1,599	1,259	1,856	1,065
Net loss from continuing operations
-5,709	-2,736	-1,275	2,754	-4,609	-3,587	-5,704	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income from discontinued operations, net of income tax
0	0	0	56,119	5,405	5,727	5,235	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)
-5,709	-2,736	-1,275	58,873	796	2,140	-469	2,102	14,019	249	-35	-12,913	2,887	13,734	1,300	-43,075	594	-334	-775	-588	-4,153	1,069	284	-1,534	4,515	-261	-373	-1,467	-992	1,969	-721	-7,117	-1,768	2,329	1,373	-861	3,811	3,279	1,888
Loss per share continuing operations - basic (usd per share)
-0.15	-0.07	-0.03	0.07	-0.12	-0.10	-0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss per share continuing operations - diluted (usd per share)
-0.15	-0.07	-0.03	0.07	-0.12	-0.10	-0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income per share discontinued operations - basic (usd per share)
0.00	0.00	0.00	1.50	0.14	0.15	0.14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income per share discontinued operations - diluted (usd per share)
0.00	0.00	0.00	1.50	0.14	0.15	0.14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income (loss) per share
Basic (in usd per share)
-0.15	-0.07	-0.03	1.57	0.02	0.06	-0.01	0.05	0.38	0.01	0.00	-0.35	0.08	0.37	0.04	-1.20	0.02	-0.01	-0.02	-0.01	-0.12	0.03	0.01	-0.04	0.13	-0.01	-0.01	-0.04	-0.03	0.06	-0.02	-0.27	-0.07	0.09	0.05	-0.03	0.15	0.13	0.08
Diluted (in usd per share)
-0.15	-0.07	-0.03	1.57	0.02	0.06	-0.01	0.06	0.37	0.01	0.00	-0.35	0.08	0.37	0.04	-1.20	0.02	-0.01	-0.02	-0.01	-0.12	0.03	0.01	-0.04	0.13	-0.01	-0.01	-0.04	-0.03	0.06	-0.02	-0.27	-0.07	0.09	0.05	-0.04	0.15	0.13	0.08
Basic weighted average shares outstanding (in shares)
37,999	37,992	37,783	37,597	37,518	37,500	37,323	37,193	37,122	37,066	36,919	36,716	36,625	36,807	36,319	36,399	36,146	36,140	35,960	-	-	-	-	35,276	35,184	35,132	34,950	34,904	34,834	34,827	34,704	26,186	25,129	25,190	25,024	24,978	24,902	24,845	24,755
Diluted weighted average shares outstanding (in shares)
37,999	37,992	37,783	37,599	37,518	37,500	37,323	36,555	37,442	37,383	36,919	35,497	37,126	37,146	36,698	36,155	36,390	36,140	35,960	-	-	-	-	35,973	35,704	35,132	34,950	34,420	34,834	35,311	34,704	25,863	25,129	25,340	25,197	25,231	25,174	25,094	25,032